Comparative Assessment of the Risk of Unfavorable Outcome after Percutaneous Coronary Interventions in Patients with IHD with Concomitant Chronic Obstructive Pulmonary Disease, Possibilities of Drug Correction
DOI:
https://doi.org/10.61841/qwahm545Keywords:
Coronary Intervention, Ischemic Heart Disease, Chronic Obstructive Pulmonary DiseaseAbstract
Objective: to make a comparative assessment of the risk of unfavorable outcome after percutaneous coronary interventions in patients with coronary heart disease with concomitant chronic obstructive pulmonary disease to determine the possibilities of drug correction. Materials and methods: Results of PCI of 726 patients with IHD made the basis of the work: group I consisted of 106 patients who underwent PCI with COPD; group II included 620 patients after PCI without COPD. Results: The presence of concomitant COPD is associated with an increased risk of hospital mortality and the development of cardiovascular complications (CVC) during the observation period after PCI. Thus, patients with COPD were statistically significantly older, female prevailed, and a more severe course was determined (Killip III, in 15.1% versus 4.1% in group II; p <0.05); predominantly 3 vascular lesions (in 60.4% versus 21.0%; p <0.05); the risk of hospital mortality (3.8% versus 0.02%; p <0.05) is higher. Arterial hypertension, smoking, dyslipidemia, and decreased glomerular filtration rate (all p <0.05) are more often diagnosed among patients with COPD as a risk factor for CVC. Regression analysis showed that the risk of unfavorable events directly correlated with age (r = 0.72), Charlson comorbidity index (r = 0.63), risk group (r = 0.58) and the frequency of COPD exacerbations (r = 0.50). Conclusions: A comparative study of CVC results showed that in IHD patients with concomitant COPD there are significant correlations of unfavorable PCI outcome (mortality, repeated revascularization, and myocardial infarction) with the main clinical characteristics of patients with COPD (CAT, mMRC, frequency of COPD exacerbations) and comorbidity index. Damage to the cardiovascular and respiratory systems forms a vicious circle of mutual complications with the need for a comprehensive examination of the patient and the formation of a high-risk group in order to optimize drug correction.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
